{
    "id": "5524f30f-789d-4f5c-8f7c-d03a475b6d34",
    "indications": {
        "text": "rivaroxaban tablet factor xa inhibitor indicated : \u2022 reduce risk stroke systemic embolism nonvalvular atrial fibrillation ( 1.1 ) \u2022 treatment deep vein thrombosis ( dvt ) ( 1.2 ) \u2022 treatment pulmonary embolism ( pe ) ( 1.3 ) \u2022 reduction risk recurrence dvt pe ( 1.4 ) \u2022 prophylaxis dvt , may lead pe patients undergoing knee hip replacement surgery ( 1.5 ) \u2022 prophylaxis venous thromboembolism ( vte ) acutely ill medical patients ( 1.6 ) \u2022 reduce risk major cardiovascular events patients coronary artery disease ( cad ) ( 1.7 ) \u2022 reduce risk major thrombotic vascular events patients peripheral artery disease ( pad ) , including patients recent lower extremity revascularization due symptomatic pad ( 1.8 ) \u2022 treatment vte reduction risk recurrent vte pediatric patients birth less 18 years ( 1.9 ) \u2022 thromboprophylaxis pediatric patients 2 years older congenital heart disease fontan procedure ( 1.10 )",
        "doid_entities": [
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "atrial fibrillation (DOID:0060224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060224"
            },
            {
                "text": "thrombosis (DOID:0060903)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060903"
            },
            {
                "text": "pulmonary embolism (DOID:9477)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9477"
            },
            {
                "text": "coronary artery disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "artery disease (DOID:0050828)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050828"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "peripheral artery disease (DOID:0050830)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050830"
            },
            {
                "text": "congenital heart disease (DOID:1682)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1682"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 nonvalvular atrial fibrillation : 15 20 mg , daily food ( 2.1 ) \u2022 treatment dvt and/or pe : 15 mg orally twice daily food first 21 days followed 20 mg orally daily food remaining treatment ( 2.1 ) \u2022 reduction risk recurrence dvt and/or pe patients continued risk dvt and/or pe : 10 mg daily without food , least 6 months standard anticoagulant treatment ( 2.1 ) \u2022 prophylaxis dvt following hip knee replacement surgery : 10 mg orally daily without food ( 2.1 ) \u2022 prophylaxis vte acutely ill medical patients risk thromboembolic complications high risk bleeding : 10 mg daily , without food , hospital hospital discharge total recommended duration 31 39 days ( 2.1 ) \u2022 cad pad : 2.5 mg orally twice daily without food , combination aspirin ( 75 100 mg ) daily ( 2.1 ) \u2022 pediatric patients : dosing recommendations full prescribing information ( 2.2 )",
        "doid_entities": [
            {
                "text": "atrial fibrillation (DOID:0060224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060224"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "rivaroxaban tablets , usp available strengths packages listed : 2.5 mg tablets : light yellow yellow round biconvex film-coated tablets debossed \u201c 9 \u201d one side \u201c c \u201d side . ndc 46708-683-60 bottle 60 tablets child resistant closure ndc 46708-683-45 bottle 180 tablets child resistant closure ndc 46708-683-91 bottle 1000 tablets ndc 46708-683-10 100 ( 10 x 10 ) tablets unit dose blister pack 10 mg tablets round , pink , biconvex film-coated tablets debossed \u201c l \u201d one side \u201c 10 \u201d side . tablets supplied packages listed : ndc 46708-346-30 bottle 30 tablets child resistant closure ndc 46708-346-91 bottle 1000 tablets ndc 46708-346-10 100 ( 10 x 10 ) tablets unit dose blister pack 15 mg tablets round , brown , film-coated biconvex tablets debossed \u2018 504 \u2019 one side plain side . tablets supplied packages listed : ndc 46708-347-30 bottle 30 tablets child resistant closure ndc 46708-347-91 bottle 1000 tablets ndc 46708-347-10 100 ( 10 x 10 ) tablets unit dose blister pack 20 mg tablets triangle shaped , brown , film-coated tablets debossed \u2018 505 \u2019 one side plain side . tablets supplied packages listed : ndc 46708-348-30 bottle 30 tablets child resistant closure ndc 46708-348-91 bottle 1000 tablets ndc 46708-348-10 100 ( 10 x 10 ) tablets unit dose blister pack starter pack treatment deep vein thrombosis treatment pulmonary embolism : ndc 46708-240-51 30-day starter blister pack containing 51 tablets : 42 tablets 15 mg 9 tablets 20 mg store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . preserve well-closed containers . keep reach children .",
    "adverseReactions": "rivaroxaban tablets contraindicated patients : \u00b7 active pathological bleeding [ ( 5.2 ) ] \u00b7 severe hypersensitivity reaction rivaroxaban tablets ( e.g . , anaphylactic ) [ ( 6.2 ) ]",
    "ingredients": [
        {
            "name": "RIVAROXABAN",
            "code": "9NDF7JZ4M3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        }
    ],
    "organization": "Alembic Pharmaceuticals Limited",
    "name": "RIVAROXABAN",
    "effectiveTime": "20250130",
    "indications_original": "Rivaroxaban tablet is a factor Xa inhibitor indicated: \u2022 to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation (1.1) \u2022 for treatment of deep vein thrombosis (DVT) (1.2) \u2022 for treatment of pulmonary embolism (PE) (1.3) \u2022 for reduction in the risk of recurrence of DVT or PE (1.4) \u2022 for prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery (1.5) \u2022 for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients (1.6) \u2022 to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) (1.7) \u2022 to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD (1.8) \u2022 for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years (1.9) \u2022 for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure (1.10)",
    "contraindications_original": "\u2022 Nonvalvular Atrial Fibrillation : 15 or 20 mg, once daily with food (2.1) \u2022 Treatment of DVT and/or PE : 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment (2.1) \u2022 Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE : 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment (2.1) \u2022 Prophylaxis of DVT Following Hip or Knee Replacement Surgery : 10 mg orally once daily with or without food (2.1) \u2022 Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding : 10 mg once daily, with or without food, in hospital and after hospital discharge for a total recommended duration of 31 to 39 days (2.1) \u2022 CAD or PAD : 2.5 mg orally twice daily with or without food, in combination with aspirin (75 to 100 mg) once daily (2.1) \u2022 Pediatric Patients : See dosing recommendations in the Full Prescribing Information (2.2)",
    "warningsAndPrecautions_original": "Rivaroxaban tablets, USP are available in the strengths and packages listed below: 2.5 mg tablets: Light yellow to yellow round biconvex film-coated tablets debossed with \u201c9\u201d on one side and \u201cC\u201d on other side. NDC 46708-683-60\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Bottle of 60 tablets with child resistant closure NDC 46708-683-45\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Bottle of 180 tablets with child resistant closure NDC 46708-683-91\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Bottle of 1000 tablets NDC 46708-683-10\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 100 (10 x 10) tablets unit dose blister pack\n                      10 mg tablets are round, pink, biconvex film-coated tablets debossed with \u201cL\u201d on one side and \u201c10\u201d on the other side. The tablets are supplied in the packages listed: NDC 46708-346-30\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Bottle of 30 tablets with child resistant closure NDC 46708-346-91\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Bottle of 1000 tablets NDC 46708-346-10\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 100 (10 x 10) tablets unit dose blister pack\u00a0\n                      15 mg tablets are round, brown, film-coated biconvex tablets debossed with \u2018504\u2019 on one side and plain on the other side. The tablets are supplied in the packages listed: NDC 46708-347-30\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Bottle of 30 tablets with child resistant closure NDC 46708-347-91\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Bottle of 1000 tablets NDC 46708-347-10\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 100 (10 x 10) tablets unit dose blister pack\n                      20 mg tablets are triangle shaped, brown, film-coated tablets debossed with \u2018505\u2019 on one side and plain on the other side. The tablets are supplied in the packages listed: NDC 46708-348-30\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Bottle of 30 tablets with child resistant closure NDC 46708-348-91\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Bottle of 1000 tablets NDC 46708-348-10\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 100 (10 x 10) tablets unit dose blister pack\n                      Starter Pack for treatment of deep vein thrombosis and treatment of pulmonary embolism: NDC 46708-240-51\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a030-day starter blister pack containing 51 tablets: 42 tablets of 15 mg and 9 tablets of 20 mg\n                      Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].\u00a0Preserve in well-closed containers. Keep out of the reach of children.",
    "adverseReactions_original": "Rivaroxaban tablets are\u00a0contraindicated in patients with: \n                  \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 active pathological bleeding [see Warnings and Precautions (5.2)]\n                  \n                  \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 severe hypersensitivity reaction to rivaroxaban\u00a0tablets (e.g., anaphylactic reactions) [see Adverse Reactions (6.2)]",
    "drug": [
        {
            "name": "RIVAROXABAN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        }
    ]
}